NO324278B1 - Anvendelse av progesteron for fremstilling av et medikament for behandling eller redusering av ischemi - Google Patents
Anvendelse av progesteron for fremstilling av et medikament for behandling eller redusering av ischemi Download PDFInfo
- Publication number
- NO324278B1 NO324278B1 NO19992140A NO992140A NO324278B1 NO 324278 B1 NO324278 B1 NO 324278B1 NO 19992140 A NO19992140 A NO 19992140A NO 992140 A NO992140 A NO 992140A NO 324278 B1 NO324278 B1 NO 324278B1
- Authority
- NO
- Norway
- Prior art keywords
- progesterone
- treatment
- ischemia
- myocardial ischemia
- reduction
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims description 59
- 239000000186 progesterone Substances 0.000 title claims description 28
- 229960003387 progesterone Drugs 0.000 title claims description 28
- 239000003814 drug Substances 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 238000011282 treatment Methods 0.000 title description 15
- 208000028867 ischemia Diseases 0.000 title description 11
- 230000009467 reduction Effects 0.000 title description 11
- 229920000642 polymer Polymers 0.000 claims description 24
- 229940011871 estrogen Drugs 0.000 claims description 16
- 239000000262 estrogen Substances 0.000 claims description 16
- 208000031225 myocardial ischemia Diseases 0.000 claims description 14
- 206010002383 Angina Pectoris Diseases 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 3
- 239000000583 progesterone congener Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 238000009472 formulation Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 238000009164 estrogen replacement therapy Methods 0.000 description 9
- 229920002125 Sokalan® Polymers 0.000 description 5
- 230000035587 bioadhesion Effects 0.000 description 5
- 239000000227 bioadhesive Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 206010002388 Angina unstable Diseases 0.000 description 3
- 235000019482 Palm oil Nutrition 0.000 description 3
- 229920000148 Polycarbophil calcium Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 230000007211 cardiovascular event Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- GQOKIYDTHHZSCJ-UHFFFAOYSA-M dimethyl-bis(prop-2-enyl)azanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC=C GQOKIYDTHHZSCJ-UHFFFAOYSA-M 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 238000002657 hormone replacement therapy Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002540 palm oil Substances 0.000 description 3
- 229950005134 polycarbophil Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000005800 cardiovascular problem Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940083544 estradiol 2 mg Drugs 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 229940018198 medroxyprogesterone acetate 5 mg Drugs 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 229940085237 carbomer-980 Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229940083543 estradiol 1 mg Drugs 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- -1 unlike MPA Substances 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/743,153 US5985861A (en) | 1996-11-04 | 1996-11-04 | Progesterone for treating or reducing ischemia |
| PCT/US1997/020923 WO1998019681A1 (en) | 1996-11-04 | 1997-11-04 | Progesterone for treating or reducing ischemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO992140D0 NO992140D0 (no) | 1999-05-03 |
| NO992140L NO992140L (no) | 1999-05-04 |
| NO324278B1 true NO324278B1 (no) | 2007-09-17 |
Family
ID=24987712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19992140A NO324278B1 (no) | 1996-11-04 | 1999-05-03 | Anvendelse av progesteron for fremstilling av et medikament for behandling eller redusering av ischemi |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US5985861A (hu) |
| EP (1) | EP0956023B1 (hu) |
| KR (1) | KR100434623B1 (hu) |
| CN (1) | CN100341512C (hu) |
| AR (1) | AR009407A1 (hu) |
| AT (1) | ATE321558T1 (hu) |
| AU (1) | AU715740C (hu) |
| BR (1) | BR9710918A (hu) |
| CA (1) | CA2270565C (hu) |
| DE (1) | DE69735598T2 (hu) |
| DK (1) | DK0956023T3 (hu) |
| ES (1) | ES2262196T3 (hu) |
| GE (1) | GEP20022630B (hu) |
| HK (1) | HK1020534A1 (hu) |
| HU (1) | HUP9904045A3 (hu) |
| IL (1) | IL127455A (hu) |
| LV (1) | LV12342B (hu) |
| MA (1) | MA24391A1 (hu) |
| MY (1) | MY121627A (hu) |
| NO (1) | NO324278B1 (hu) |
| NZ (1) | NZ335306A (hu) |
| PE (1) | PE9899A1 (hu) |
| PT (1) | PT956023E (hu) |
| RO (1) | RO120607B1 (hu) |
| UA (1) | UA66772C2 (hu) |
| WO (1) | WO1998019681A1 (hu) |
| ZA (1) | ZA979862B (hu) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6602487B1 (en) | 1997-02-26 | 2003-08-05 | Dimera Incorporated | Methods and tests for producing and for inhibiting coronary artery vasospasms |
| US6056972A (en) * | 1997-02-26 | 2000-05-02 | Dimera, Llc | Method for reducing coronary artery reactivity |
| DE69819748T2 (de) | 1997-09-12 | 2004-09-30 | Columbia Laboratories (Bermuda) Ltd. | Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen |
| US20040234606A1 (en) * | 1997-09-12 | 2004-11-25 | Levine Howard L. | Localized vaginal delivery without detrimental blood levels |
| GB0107383D0 (en) * | 2001-03-23 | 2001-05-16 | Univ Edinburgh | Lipid profile modulation |
| US20080182841A1 (en) * | 2001-10-29 | 2008-07-31 | Levine Howard L | Vaginally administered anti-dysrhythmic agents for treating pelvic pain |
| US8425892B2 (en) | 2001-10-29 | 2013-04-23 | Columbia Laboratories, Inc. | Extended, controlled-release pharmaceutical compositions using charged polymers |
| US20030114394A1 (en) * | 2001-10-29 | 2003-06-19 | Levine Howard L. | Vaginally administered anti-dysrhythmic agents for treating pelvic pain |
| US7572780B2 (en) | 2003-01-21 | 2009-08-11 | Dimera, Incorporated | Method and kit for reducing the symptoms of peripheral vascular disease |
| AU2004233997C1 (en) * | 2003-04-29 | 2014-01-30 | Massachusetts Institiute Of Technology | Methods and devices for the sustained release of multiple drugs |
| DE102005027004B4 (de) * | 2005-06-10 | 2020-03-19 | Continental Automotive Gmbh | Scheibenwaschvorrichtung |
| US8828981B2 (en) | 2007-02-06 | 2014-09-09 | George Creasy | Progesterone for the treatment or prevention of spontaneous preterm birth |
| PL2249757T3 (pl) * | 2008-02-04 | 2017-12-29 | Ferring B.V. | Monolityczne pierścienie dopochwowe zawierające progesteron oraz metody ich wytwarzania i stosowania |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| JP6285866B2 (ja) | 2011-11-23 | 2018-02-28 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然複合ホルモン補充製剤および療法 |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| KR20170005819A (ko) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 천연 복합 호르몬 대체 제형 및 요법 |
| RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US11512107B2 (en) | 2018-09-07 | 2022-11-29 | Trustees Of Dartmouth College | Methods for assembly of tetracyclic compounds by stereoselective C9-C10 bond formation |
| JP2021535183A (ja) * | 2018-09-07 | 2021-12-16 | トラスティーズ・オヴ・ダートマス・カレッジ | Ｃ１９骨格およびステロイドならびにそれらの使用および製造方法 |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1124906A1 (ru) * | 1982-05-25 | 1984-11-23 | Ивановский государственный медицинский институт им.А.С.Бубнова | Способ коррекции ишемических повреждений консервированной донорской почки |
| WO1985002092A1 (en) * | 1983-11-14 | 1985-05-23 | Bio-Mimetics Inc. | Bioadhesive compositions and methods of treatment therewith |
| US5543150A (en) * | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
-
1996
- 1996-11-04 US US08/743,153 patent/US5985861A/en not_active Expired - Lifetime
-
1997
- 1997-11-03 ZA ZA9709862A patent/ZA979862B/xx unknown
- 1997-11-03 MA MA24853A patent/MA24391A1/fr unknown
- 1997-11-04 HU HU9904045A patent/HUP9904045A3/hu unknown
- 1997-11-04 MY MYPI97005220A patent/MY121627A/en unknown
- 1997-11-04 WO PCT/US1997/020923 patent/WO1998019681A1/en active IP Right Grant
- 1997-11-04 EP EP97946681A patent/EP0956023B1/en not_active Expired - Lifetime
- 1997-11-04 AR ARP970105144A patent/AR009407A1/es unknown
- 1997-11-04 NZ NZ335306A patent/NZ335306A/xx not_active IP Right Cessation
- 1997-11-04 CN CNB971994145A patent/CN100341512C/zh not_active Expired - Fee Related
- 1997-11-04 RO RO99-00508A patent/RO120607B1/ro unknown
- 1997-11-04 DK DK97946681T patent/DK0956023T3/da active
- 1997-11-04 UA UA99052985A patent/UA66772C2/uk unknown
- 1997-11-04 AU AU51801/98A patent/AU715740C/en not_active Ceased
- 1997-11-04 CA CA002270565A patent/CA2270565C/en not_active Expired - Fee Related
- 1997-11-04 GE GEAP19974830A patent/GEP20022630B/en unknown
- 1997-11-04 PE PE1997000985A patent/PE9899A1/es not_active Application Discontinuation
- 1997-11-04 BR BR9710918-5A patent/BR9710918A/pt not_active Application Discontinuation
- 1997-11-04 KR KR10-1999-7003965A patent/KR100434623B1/ko not_active IP Right Cessation
- 1997-11-04 AT AT97946681T patent/ATE321558T1/de not_active IP Right Cessation
- 1997-11-04 PT PT97946681T patent/PT956023E/pt unknown
- 1997-11-04 DE DE69735598T patent/DE69735598T2/de not_active Expired - Fee Related
- 1997-11-04 ES ES97946681T patent/ES2262196T3/es not_active Expired - Lifetime
-
1998
- 1998-12-09 IL IL12745598A patent/IL127455A/xx not_active IP Right Cessation
-
1999
- 1999-02-01 US US09/240,610 patent/US6054447A/en not_active Expired - Lifetime
- 1999-05-03 NO NO19992140A patent/NO324278B1/no unknown
- 1999-05-28 LV LVP-99-88A patent/LV12342B/en unknown
- 1999-11-30 HK HK99105558A patent/HK1020534A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO324278B1 (no) | Anvendelse av progesteron for fremstilling av et medikament for behandling eller redusering av ischemi | |
| Weinstein et al. | Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect | |
| Hassager et al. | The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. | |
| Clements et al. | Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. | |
| RU2330667C2 (ru) | Прогестинотерапия с регулируемым кровотечением | |
| Tremollieres et al. | Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women | |
| JPH09502724A (ja) | 新規なプロゲステロン送達方法とその効果 | |
| JPH09504037A (ja) | 肛門疾患を治療する窒素酸化物供与体及び方法 | |
| NO329830B1 (no) | Oral farmasoytisk formulering inneholdende tolterodin og med kontrollert frigivelse | |
| NO329203B1 (no) | Farmasoytiske blandinger samt anvendelser derav | |
| Harvey et al. | Exercise as an alternative to oral estrogen for amelioration of endothelial dysfunction in postmenopausal women | |
| US20200046729A1 (en) | Methods using combined oral contraceptive compositions with reduced cardiovascular effects | |
| Van Keep et al. | Potency and hepato-cellular effects of oestrogens after oral, percutaneous, and subcutaneous administration | |
| EP1594510A2 (en) | Method and kit for reducing the symptoms of peripheral vascular disease | |
| Galle et al. | Inhibition of cyclic AMP-and cyclic GMP-mediated dilations in isolated arteries by oxidized low density lipoproteins. | |
| KR100450649B1 (ko) | 호르몬약물및에스트로겐결핍을치유하기위한그의용도 | |
| Zoma et al. | Effects of combined use of sildenafil citrate (Viagra) and 17β-estradiol on ovine coronary and uterine hemodynamics | |
| Ladipo et al. | Contraceptive implants | |
| Kafrissen | A norgestimate-containing oral contraceptive: review of clinical studies | |
| MXPA99004130A (es) | Progesterona para el tratamiento o la reduccion de isquemia | |
| SCHIFF et al. | Benefits of estrogen replacement | |
| Fioretti et al. | Clinical and metabolic effects of a pill containing 30 mcg ethinylestradiol plus 75 mcg gestodene | |
| Haenggi et al. | A new peroral estrogen/progestin combination for postmenopausal hormonal substitution: an open multicentric field study | |
| Ferguson et al. | Effect of captopril and propranolol, alone and in combination, on the responses to isometric and dynamic exercise in normotensive and hypertensive men | |
| JP2002503215A (ja) | 虚血を治療又は抑制するためのプロゲステロン |